Advertisement

PharmacoEconomics & Outcomes News

, Volume 800, Issue 1, pp 11–11 | Cite as

Allopurinol/lesinurad cost effective for gout/hyperuricaemia

Clinical study
  • 11 Downloads

Reference

  1. Ruggeri M, et al. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy. PharmacoEconomics : 19 Mar 2018. Available from: URL: http://doi.org/10.1007/s40273-018-0643-4

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations